Clinical Trials Browser

Multiple Myeloma × spartalizumab × Clear all

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1 Completed

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02331368 2018-07-27

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Phase 2 Completed

32 enrolled 8 charts

Multiple Myeloma